1
|
Omrani V, Fardid R, Alavi M, Haddadi G, Takhshid MA. Protective effects of Panax Ginseng against 131I-induced genotoxicity in patients with differentiated thyroid cancer. J Cancer Res Ther 2024; 20:304-310. [PMID: 38554338 DOI: 10.4103/jcrt.jcrt_683_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Accepted: 10/06/2022] [Indexed: 04/01/2024]
Abstract
BACKGROUND Radioiodine (131I) therapy (RAIT) is associated with oxidative stress (OS)-induced DNA damage in patients with differentiated thyroid cancer (DTC). The goal of this study was to evaluate the possible ameliorating effects of Panax Ginseng (PG) on RAIT-induced genotoxicity in patients with DTC. MATERIALS AND METHODS Forty DTC patients who had received 131I (100 to 175 mCi) were enrolled in this study. The patients were randomly classified (n = 10) into control, placebo, PG1 groups (receiving 500 mg/day of PG for 2 days before RAIT), and PG2 group (receiving 500 mg/day of PG for 2 days before to 1 day after RAIT). Blood samples were collected before and 2 days after RAIT. Lymphocyte micronuclei (MN) frequency was measured using the MN assay. Serum total antioxidant capacity (TAC) and ischemia-modified albumin (IMA) were measured using colorimetric assays. Serum albumin, blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were measured using commercial kits. RESULTS The mean of baseline MN frequency was the same in the four groups. RAIT increased the MN frequencies to at least three times the baseline values in the control (39 ± 5) and placebo groups (38 ± 6) (P < 0.001). PG caused a significant decrease in the MN frequencies in the treated groups compared to the control and placebo groups (P < 0.001). RAIT and PG administration had no significant effects on the serum IMA, TAC, and markers of liver and kidney toxicity. CONCLUSION PG could be considered a useful remedy for the protection against RAIT-induced chromosomal damage in DCT patients.
Collapse
Affiliation(s)
- Vida Omrani
- Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Reza Fardid
- Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
- Ionizing and Non-Ionizing Radiation Protection Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mehrosadat Alavi
- Ionizing and Non-Ionizing Radiation Protection Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
- Department of Nuclear Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
- Department of Nuclear Medicine, Namazi Hospital, Zand Street, Shiraz, Iran
| | - Golamhassan Haddadi
- Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
- Ionizing and Non-Ionizing Radiation Protection Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mohammad Ali Takhshid
- Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Science, Shiraz, Iran
| |
Collapse
|
2
|
Song M, Liu Q, Sun W, Zhang H. Crosstalk between Thyroid Carcinoma and Tumor-Correlated Immune Cells in the Tumor Microenvironment. Cancers (Basel) 2023; 15:2863. [PMID: 37345200 DOI: 10.3390/cancers15102863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2023] [Revised: 05/07/2023] [Accepted: 05/19/2023] [Indexed: 06/23/2023] Open
Abstract
Thyroid cancer (TC) is the most common malignancy in the endocrine system. Although most TC can achieve a desirable prognosis, some refractory thyroid carcinomas, including radioiodine-refractory differentiated thyroid cancer, as well as anaplastic thyroid carcinoma, face a myriad of difficulties in clinical treatment. These types of tumors contribute to the majority of TC deaths due to limited initial therapy, recurrence, and metastasis of the tumor and tumor resistance to current clinically targeted drugs, which ultimately lead to treatment failure. At present, a growing number of studies have demonstrated crosstalk between TC and tumor-associated immune cells, which affects tumor deterioration and metastasis through distinct signal transduction or receptor activation. Current immunotherapy focuses primarily on cutting off the interaction between tumor cells and immune cells. Since the advent of immunotherapy, scholars have discovered targets for TC immunotherapy, which also provides new strategies for TC treatment. This review methodically and intensively summarizes the current understanding and mechanism of the crosstalk between distinct types of TC and immune cells, as well as potential immunotherapy strategies and clinical research results in the area of the tumor immune microenvironment. We aim to explore the current research advances to formulate better individualized treatment strategies for TC patients and to provide clues and references for the study of potential immune checkpoints and the development of immunotherapy technologies.
Collapse
Affiliation(s)
- Mingyuan Song
- Department of Thyroid Surgery, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang 110001, China
| | - Qi Liu
- Department of Thyroid Surgery, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang 110001, China
| | - Wei Sun
- Department of Thyroid Surgery, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang 110001, China
| | - Hao Zhang
- Department of Thyroid Surgery, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang 110001, China
| |
Collapse
|
3
|
Piscopo L, Volpe F, Nappi C, Zampella E, Manganelli M, Matrisciano F, Totaro P, Pace L, Maurea S, Cuocolo A, Klain M. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study. Curr Oncol 2022; 30:37-44. [PMID: 36661652 PMCID: PMC9857292 DOI: 10.3390/curroncol30010003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 12/14/2022] [Accepted: 12/18/2022] [Indexed: 12/24/2022] Open
Abstract
Second primary malignancies (SPM) are described as any primary, not synchronous, malignancy arising in a different anatomical district, with confirmed histological diagnosis. Age at diagnosis, previous non-thyroidal primary malignancy, and radioactive iodine (RAI) therapy have been proposed as independent risk factors for SPM. RAI therapy is a standard treatment for moderate-high risk differentiated thyroid cancer (DTC), and its effect on the development of SPM has become a critical topic in DTC treatment. The purpose of this retrospective single-center study was to investigate the occurrence and the possible association of non-thyroidal SPM diagnosed after DTC and RAI therapy in a cohort of 1326 consecutive DTC patients referred at our Institution for RAI treatment from 1993 to 2009. Eighty-nine patients with ages ≤ 18 years at the time of DTC diagnosis or with a follow-up of ≤12 months were excluded from the final analysis. All patients underwent a complete clinical and hematological follow-up every 6 months for a minimum of 12 months. During follow-up (mean 89 ± 73 months), 25 patients (2%) had an SPM diagnosis (mean 133 ± 73 months). The most common site of the second malignancy was the breast, accounting for 32% of all SPM, followed by colon-rectal cancer (16%), leukemia, and gynecological and kidney cancer (4%). At Cox univariable regression analysis, age at DTC diagnosis (p < 0.001), age ≥55 years (p < 0.001) and follow-up duration (p < 0.004) were associated with SPM onset, while no significant association was observed with the administered activity of radioiodine. In conclusion, our data suggest that the older a person gets, the more sharply the likelihood of developing additional diseases, such as PMS, increases. Similarly, for follow-up, the more a patient is followed up clinically over time, the higher the risk of new diagnoses increases.
Collapse
Affiliation(s)
- Leandra Piscopo
- Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy
| | - Fabio Volpe
- Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy
| | - Carmela Nappi
- Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy
| | - Emilia Zampella
- Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy
| | | | - Francesca Matrisciano
- Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy
| | - Pasquale Totaro
- Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy
| | - Leonardo Pace
- Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Fisciano, Italy
| | - Simone Maurea
- Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy
| | - Alberto Cuocolo
- Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy
| | - Michele Klain
- Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy
| |
Collapse
|
4
|
Wang C, Shen Y, Zhang Y, Guo F, Li Q, Zhang H, Han X, Zhao H, Yang Z. Metachronous Multiple Primary Carcinoma With Acute Promyelocytic Leukemia: 2 Cases Report and Literature Review. Front Oncol 2022; 12:893319. [PMID: 35756676 PMCID: PMC9214198 DOI: 10.3389/fonc.2022.893319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Accepted: 05/17/2022] [Indexed: 11/24/2022] Open
Abstract
The co-occurrence of multiple primary cancers with hematological malignancies is uncommon, and acute promyelocytic leukemia (APL) with MPC is even rarer, with only a few cases reported in the literature. Herein, we introduce the diagnosis and treatment of 2 cases of MPC complicated with APL in our hospital and review the relevant literature. Both patients were primary solid tumor patients and were treated with surgery and chemotherapy, and had stable disease (SD). However, more than 1 year after the primary tumor was diagnosed, clinical symptoms were found and APL was diagnosed. Both patients received standard remission-induction therapy, but unfortunately died in the short term due to hemorrhagic complications. In conclusion, treatment of hematological neoplasms, especially acute leukemia combined with multiple primary cancers, is challenging. The prognostic factors and survival analysis of MPC patients with combined APL still need further clinical research and analysis.
Collapse
Affiliation(s)
- Cong Wang
- Department of Hematology, Wuwei Tumor Hospital, Wuwei, China
| | - Yamei Shen
- Wuwei Institute of Hematology, Wuwei, China
| | - Yuxia Zhang
- Department of Hematology, Wuwei Tumor Hospital, Wuwei, China
| | - Fahui Guo
- Wuwei Institute of Hematology, Wuwei, China
| | - Qian Li
- Department of Hematology, Wuwei Tumor Hospital, Wuwei, China
| | - Huahua Zhang
- Department of Hematology, Wuwei Tumor Hospital, Wuwei, China
| | | | | | | |
Collapse
|
5
|
Sousos N, Ní Leathlobhair M, Simoglou Karali C, Louka E, Bienz N, Royston D, Clark SA, Hamblin A, Howard K, Mathews V, George B, Roy A, Psaila B, Wedge DC, Mead AJ. In utero origin of myelofibrosis presenting in adult monozygotic twins. Nat Med 2022; 28:1207-1211. [PMID: 35637336 PMCID: PMC9205768 DOI: 10.1038/s41591-022-01793-4] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2021] [Accepted: 03/22/2022] [Indexed: 12/11/2022]
Abstract
The latency between acquisition of an initiating somatic driver mutation by a single-cell and clinical presentation with cancer is largely unknown. We describe a remarkable case of monozygotic twins presenting with CALR mutation-positive myeloproliferative neoplasms (MPNs) (aged 37 and 38 years), with a clinical phenotype of primary myelofibrosis. The CALR mutation was absent in T cells and dermal fibroblasts, confirming somatic acquisition. Whole-genome sequencing lineage tracing revealed a common clonal origin of the CALR-mutant MPN clone, which occurred in utero followed by twin-to-twin transplacental transmission and subsequent similar disease latency. Index sorting and single-colony genotyping revealed phenotypic hematopoietic stem cells (HSCs) as the likely MPN-propagating cell. Furthermore, neonatal blood spot analysis confirmed in utero origin of the JAK2V617F mutation in a patient presenting with polycythemia vera (aged 34 years). These findings provide a unique window into the prolonged evolutionary dynamics of MPNs and fitness advantage exerted by MPN-associated driver mutations in HSCs.
Collapse
Affiliation(s)
- Nikolaos Sousos
- Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK
- Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Máire Ní Leathlobhair
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
- Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK
- Department of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics and Microbiology, Trinity College Dublin, Dublin, Ireland
| | - Christina Simoglou Karali
- Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK
| | - Eleni Louka
- Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK
| | - Nicola Bienz
- Haematology Service, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK
| | - Daniel Royston
- Department of Cellular Pathology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Sally-Ann Clark
- Flow Cytometry Facility, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Angela Hamblin
- Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK
| | - Kieran Howard
- National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK
| | - Vikram Mathews
- Department of Haematology, Christian Medical College, Vellore, India
| | - Biju George
- Department of Haematology, Christian Medical College, Vellore, India
| | - Anindita Roy
- Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK
- Department of Paediatrics, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Bethan Psaila
- Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK
- Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - David C Wedge
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.
- Manchester Cancer Research Centre, The University of Manchester, Manchester, UK.
| | - Adam J Mead
- Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK.
- Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
| |
Collapse
|
6
|
Jonklaas J. Impact of Nasolacrimal Dysfunction in Thyroid Cancer Survivors. Thyroid 2022; 32:483-485. [PMID: 35180829 PMCID: PMC9271331 DOI: 10.1089/thy.2022.0095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Jacqueline Jonklaas
- Division of Endocrinology, Georgetown University, Washington, District of Columbia, USA
| |
Collapse
|
7
|
Pasqual E, Schonfeld S, Morton LM, Villoing D, Lee C, Berrington de Gonzalez A, Kitahara CM. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies. J Clin Oncol 2022; 40:1439-1449. [PMID: 35044839 PMCID: PMC9061144 DOI: 10.1200/jco.21.01841] [Citation(s) in RCA: 37] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
PURPOSE Since the 1980s, both the incidence of differentiated thyroid cancer (DTC) and use of radioactive iodine (RAI) treatment increased markedly. RAI has been associated with an increased risk of leukemia, but risks of second solid malignancies remain unclear. We aimed to quantify risks of second malignancies associated with RAI treatment for DTC in children and young adults, who are more susceptible than older adults to the late effects of radiation. METHODS Using nine US SEER cancer registries (1975-2017), we estimated relative risks (RRs) for solid and hematologic malignancies associated with RAI (yes v no or unknown) using Poisson regression among ≥ 5- and ≥ 2-year survivors of nonmetastatic DTC diagnosed before age 45 years, respectively. RESULTS Among 27,050 ≥ 5-year survivors (median follow-up = 15 years), RAI treatment (45%) was associated with increased risk of solid malignancies (RR = 1.23; 95% CI, 1.11 to 1.37). Risks were increased for uterine cancer (RR = 1.55; 95% CI, 1.03 to 2.32) and nonsignificantly for cancers of the salivary gland (RR = 2.15; 95% CI, 0.91 to 5.08), stomach (RR = 1.61; 95% CI, 0.70 to 3.69), lung (RR = 1.42; 95% CI, 0.97 to 2.08), and female breast (RR = 1.18; 95% CI, 0.99 to 1.40). Risks of total solid and female breast cancer, the most common cancer type, were highest among ≥ 20-year DTC survivors (RRsolid = 1.47; 95% CI, 1.24 to 1.74; RRbreast = 1.46; 95% CI, 1.10 to 1.95). Among 32,171 ≥ 2-year survivors, RAI was associated with increased risk of hematologic malignancies (RR = 1.51; 95% CI, 1.08 to 2.01), including leukemia (RR = 1.92; 95% CI, 1.04 to 3.56). We estimated that 6% of solid and 14% of hematologic malignancies in pediatric and young adult DTC survivors may be attributable to RAI. CONCLUSION In addition to leukemia, RAI treatment for childhood and young-adulthood DTC was associated with increased risks of several solid cancers, particularly more than 20 years after exposure, supporting the need for long-term surveillance of these patients.
Collapse
Affiliation(s)
- Elisa Pasqual
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Sara Schonfeld
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Lindsay M. Morton
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | | | - Choonsik Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | | | - Cari M. Kitahara
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD,Cari M. Kitahara, PhD, MHS, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr, Rm. 7E-456, Bethesda, MD 20892; e-mail:
| |
Collapse
|
8
|
Kim S, Bang JI, Boo D, Kim B, Choi IY, Ko S, Yoo IR, Kim K, Kim J, Joo Y, Ryoo HG, Paeng JC, Park JM, Jang W, Kim B, Chung Y, Yang D, Yoo S, Lee HY. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics. Eur J Nucl Med Mol Imaging 2022; 49:3547-3556. [PMID: 35362796 DOI: 10.1007/s00259-022-05779-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 03/22/2022] [Indexed: 11/29/2022]
Abstract
PURPOSE Risk of second primary malignancy (SPM) after radioiodine (RAI) therapy has been continuously debated. The aim of this study is to identify the risk of SPM in thyroid cancer (TC) patients with RAI compared with TC patients without RAI from matched cohort. METHODS Retrospective propensity-matched cohorts were constructed across 4 hospitals in South Korea via the Observational Health Data Science and Informatics (OHDSI), and electrical health records were converted to data of common data model. TC patients who received RAI therapy constituted the target group, whereas TC patients without RAI therapy constituted the comparative group with 1:1 propensity score matching. Hazard ratio (HR) by Cox proportional hazard model was used to estimate the risk of SPM, and meta-analysis was performed to pool the HRs. RESULTS Among a total of 24,318 patients, 5,374 patients from each group were analyzed (mean age 48.9 and 49.2, women 79.4% and 79.5% for target and comparative group, respectively). All hazard ratios of SPM in TC patients with RAI therapy were ≤ 1 based on 95% confidence interval(CI) from full or subgroup analyses according to thyroid cancer stage, time-at-risk period, SPM subtype (hematologic or non-hematologic), and initial age (< 30 years or ≥ 30 years). The HR within the target group was not significantly higher (< 1) in patients who received over 3.7 GBq of I-131 compared with patients who received less than 3.7 GBq of I-131 based on 95% CI. CONCLUSION There was no significant difference of the SPM risk between TC patients treated with I-131 and propensity-matched TC patients without I-131 therapy.
Collapse
Affiliation(s)
- Seok Kim
- Office of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea
| | - Ji-In Bang
- Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea
| | - Dachung Boo
- Office of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea
| | - Borham Kim
- Office of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea
| | - In Young Choi
- Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - SooJeong Ko
- Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Department of Biomedicine & Health Sciences, The Catholic University of Korea, Seoul, Republic of Korea
| | - Ie Ryung Yoo
- Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
| | - Kwangsoo Kim
- Transdisciplinary Department of Medicine & Advanced Technology, Seoul National University Hospital, Seoul, Republic of Korea.,Medical Big Data Research Center, Seoul National University Medical Research Center, Seoul, Republic of Korea
| | - Junmo Kim
- Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Republic of Korea
| | - YoungHwan Joo
- Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea
| | - Hyun Gee Ryoo
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Jin Chul Paeng
- Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| | - Jung Mi Park
- Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Gyeonggido, Republic of Korea
| | - Woncheol Jang
- Department of Statistics, Seoul National University, Seoul, South Korea
| | - Byungwon Kim
- Department of Statistics, Kyungpook National University, Daegu, South Korea
| | - Yangha Chung
- Department of Statistics, Seoul National University, Seoul, South Korea
| | - Dongyoon Yang
- Department of Statistics, Seoul National University, Seoul, South Korea
| | - Sooyoung Yoo
- Office of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea.
| | - Ho-Young Lee
- Department of Nuclear Medicine, Office of eHealth Research and Business, Seoul National University Bundang Hospital, 166, Gumi-ro, Seongnam-si 436-707, Republic of Korea.
| |
Collapse
|
9
|
Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study. Eur J Nucl Med Mol Imaging 2021; 49:1661-1670. [PMID: 34773164 DOI: 10.1007/s00259-021-05608-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Accepted: 10/27/2021] [Indexed: 10/19/2022]
Abstract
PURPOSE The objective of this study was to estimate the incidence of secondary cancers and the factors associated with their development among patients who underwent radioiodine therapy (RIT) with differentiated thyroid cancer. METHODS We retrospectively collected medical records for patients who underwent first RIT between January 1, 2000, and December 31, 2005, from seven tertiary hospitals in South Korea after total thyroidectomy for differentiated thyroid cancer. Cancer incidence and calculated standardized rate ratio were compared with Korean cancer incidence data. The association between the development of secondary cancers and various parameters was analyzed by Cox-proportional hazard regression. RESULTS A total of 3106 patients were included in this study. Mean age at the time of diagnosis of thyroid cancer was 45.7 ± 13.3 years old, and 2669 (85.9%) patients were female. The follow-up period was 11.9 ± 4.6 (range, 1.2-19.6) years. A total of 183 secondary cancers, which included 162 solid and 21 hematologic cancers, occurred in 173 patients (5.6%). There was no significant difference between solid cancer incidence in our study population who underwent RIT and the overall Korean population, but the incidence of hematologic cancers and total cancer in our study was significantly higher compared with that of the Korean population. A multivariate analysis identified independent prognostic factors for the development of secondary cancer including age at 1st RIT, male, and total cumulative dose over 200 mCi. CONCLUSION We need to assess the risk benefit for patients who receive over 200 mCi of a total cumulative dose.
Collapse
|
10
|
Verburg FA, Hoffmann M, Iakovou I, Konijnenberg MW, Mihailovic J, Gabina PM, Ovčariček PP, Reiners C, Vrachimis A, Zerdoud S, Giovanella L, Luster M. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies. Eur J Nucl Med Mol Imaging 2021; 47:519-522. [PMID: 31807882 DOI: 10.1007/s00259-019-04580-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Frederik A Verburg
- EANM Thyroid Committee, Vienna, Austria. .,Department of Nuclear Medicine, University Hospital Marburg, Baldinger Straße, 35043, Marburg, Germany.
| | - Martha Hoffmann
- EANM Thyroid Committee, Vienna, Austria.,Department of Nuclear Medicine, Radiology Center, Vienna, Austria
| | - Ioannis Iakovou
- EANM Thyroid Committee, Vienna, Austria.,Academic Department of Nuclear Medicine, Aristotle University, Thessaloniki, Greece
| | - Mark W Konijnenberg
- EANM Dosimetry Committee, Vienna, Austria.,Department of Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Jasna Mihailovic
- EANM Thyroid Committee, Vienna, Austria.,Department of Radiology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.,Department of Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
| | - Pablo Minguez Gabina
- EANM Dosimetry Committee, Vienna, Austria.,Department of Medical Physics and Radiation Protection, Gurutzeta/Cruces University Hospital, Barakaldo, Spain
| | - Petra Petranović Ovčariček
- EANM Thyroid Committee, Vienna, Austria.,Department of Oncology and Nuclear medicine, University Hospital Center "Sestre milosrdnice", Zagreb, Croatia
| | - Cristoph Reiners
- Department of Nuclear Medicine, Würzburg University Hospital, Würzburg, Germany
| | - Alexis Vrachimis
- EANM Thyroid Committee, Vienna, Austria.,Department of Nuclear Medicine, German Oncology Center, University Hospital of the European University, Limassol, Cyprus
| | - Slimane Zerdoud
- EANM Thyroid Committee, Vienna, Austria.,Department of Nuclear Medicine, Nuclear Oncology and Thyroidological Oncology, University Cancer Institute - Oncopole, Toulouse, France
| | - Luca Giovanella
- EANM Thyroid Committee, Vienna, Austria.,Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Centre Imaging Institute of Southern Switzerland, Bellinzona, Switzerland.,Clinic for Nuclear Medicine, Zurich University Hospital, Zurich, Switzerland
| | - Markus Luster
- EANM Thyroid Committee, Vienna, Austria.,Department of Nuclear Medicine, University Hospital Marburg, Baldinger Straße, 35043, Marburg, Germany
| |
Collapse
|
11
|
Wang K, Li Z, Chen X, Zhang J, Xiong Y, Zhong G, Shi Y, Li Q, Zhang X, Li H, Xiang T, Foukakis T, Radivoyevitch T, Ren G. Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation. NPJ Breast Cancer 2021; 7:21. [PMID: 33654083 PMCID: PMC7925676 DOI: 10.1038/s41523-021-00228-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Accepted: 01/13/2021] [Indexed: 02/08/2023] Open
Abstract
The increased incidence of secondary hematologic malignancies (SHM) is a well-known, potentially fatal, complication after cancer treatment. It is unknown if patients with ductal carcinoma in situ (DCIS) of the breast treated with external beam radiotherapy (RT) and who survive long-term have increased risks of secondary hematologic malignancies (SHM), especially for low/intermediate-risk subsets with limited benefits from RT. DCIS patients in Surveillance, Epidemiology, and End Results (SEER) registries (1975-2016) were identified. Relative risks (RR), hazard ratio (HR), and standardized incidence ratios (SIR) were calculated to assess the SHM risk and subsequent survival times. SHM development, defined as a nonsynchronous SHM occurring ≥1 year after DCIS diagnosis, was our primary endpoint. Of 184,363 eligible patients with DCIS, 77,927 (42.3%) in the RT group, and 106,436 (57.7%) in the non-RT group, 1289 developed SHMs a median of 6.4 years (interquartile range, 3.5 to 10.3 years) after their DCIS diagnosis. Compared with DCIS patients in the non-RT group, RT was associated with increased early risk of developing acute lymphoblastic leukemia (ALL; hazard ratio, 3.15; 95% CI, 1.21 to 8.17; P = 0.02), and a delayed risk of non-Hodgkin lymphoma (NHL; hazard ratio, 1.33; 95% CI, 1.09 to 1.62; P < 0.001). This increased risk of ALL and NHL after RT was also observed in subgroup analyses restricted to low/intermediate-risk DCIS. In summary, our data suggest that RT after breast conserving surgery for DCIS patients should be cautiously tailored, especially for low and intermediate-risk patients. Long-term SHM surveillance after DCIS diagnosis is warranted.
Collapse
Affiliation(s)
- Kang Wang
- Department of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China
- Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
| | - Zhuyue Li
- West China Hospital/West China School of Nursing, Sichuan University, Chengdu, China
| | - Xingxing Chen
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - Jianjun Zhang
- Department of Epidemiology, Fairbanks School of Public Health and Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, 1050 Wishard Boulevard RG5118, Indianapolis, IN, USA
| | - Yongfu Xiong
- The First Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
| | - Guochao Zhong
- Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Yang Shi
- Division of Biostatistics and Data Science, Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, GA, USA
| | - Qing Li
- Department of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China
| | - Xiang Zhang
- Department of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China
| | - Hongyuan Li
- Department of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China
| | - Tingxiu Xiang
- Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Theodoros Foukakis
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Breast Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
| | - Tomas Radivoyevitch
- Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
| | - Guosheng Ren
- Department of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.
- Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
| |
Collapse
|
12
|
Ahtiainen V, Vaalavirta L, Tenhunen M, Joensuu H, Mäenpää H. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. Acta Oncol 2020; 59:1064-1071. [PMID: 32603613 DOI: 10.1080/0284186x.2020.1785003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Purpose: The optimal activity of radioiodine (I-131) administered for ablation therapy in papillary and follicular thyroid cancer after thyroidectomy remains unknown in a long-term (> 10 year) follow-up. Some, shorter follow-up studies suggest that activities 1.1 GBq and 3.7 GBq are equally effective. We evaluated the long-term outcomes after radioiodine treatment to extend current knowledge about the optimal ablative dose of I-131.Methods: One hundred and sixty consecutive adult patients (129 females, 31 males; mean age 46 ± 14 y, range 18-89 y) diagnosed with histologically confirmed differentiated thyroid cancer, were randomised in a prospective, phase III, open-label, single-centre study, to receive either 1.1 GBq or 3.7 GBq of I-131 after thyroidectomy. At randomisation, patients were stratified according to the histologically verified cervical lymph node status and were prepared for ablation using thyroid hormone withdrawal. No uptake in the whole-body scan with I-131 and serum thyroglobulin concentration less than 1 ng/mL at 4-8 months after treatment was considered successful ablation.Results: Median follow-up time was 13.0 years (mean 11.0 ± 4.8 y; range 0.3-17.1 y). Altogether 81 patients received 1.1 GBq with successful ablation in 45 (56%) patients. In the original study, thirty-six patients (44%) needed one or more extra administrations to replete the ablation. Of these, 4 (8.9%) and 5 (14%) patients relapsed during the follow-up, respectively. Of the 79 patients treated with 3.7 GBq 45 (57%) had successful ablation after one administration of radioiodine and 34 (43%) needed several treatments. Of these, 2 (4.4%) and 9 (26.5%) patients relapsed, respectively. The groups did not differ in the proportion of patients relapsing (p = .591).Conclusion: During follow-up of median 13 years, 3.7 GBq is not superior to 1.1 GBq in the radioiodine treatment after thyroidectomy in papillary and follicular thyroid cancer.
Collapse
Affiliation(s)
- Veera Ahtiainen
- Department of Radiation Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
- Department of Radionuclear Treatments, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
- Doctoral School in Health Sciences, University of Helsinki, Helsinki, Finland
| | - Leila Vaalavirta
- Department of Radiation Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
- Department of Radionuclear Treatments, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
| | - Mikko Tenhunen
- Department of Radiation Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
- Department of Radionuclear Treatments, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
| | - Heikki Joensuu
- Department of Radiation Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
- Department of Radionuclear Treatments, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
| | - Hanna Mäenpää
- Department of Radiation Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
- Department of Radionuclear Treatments, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
| |
Collapse
|
13
|
Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer. J Cancer Surviv 2020; 14:847-857. [PMID: 32506220 DOI: 10.1007/s11764-020-00897-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Accepted: 05/13/2020] [Indexed: 10/24/2022]
Abstract
PURPOSE Despite having a generally favorable prognosis, differentiated thyroid cancer is known to have a significant, long-term impact on the quality of life of survivors. We wished to investigate short- and long-term effects among thyroid cancer survivors following radioactive iodine therapy. METHODS We conducted eight focus groups (N = 47) to understand patients' experiences of short- and long-term effects after radioactive iodine treatment and the impact these treatment-related side effects had on patients' quality of life. We elicited responses regarding experiences with side effects following radioactive iodine treatment, particularly salivary, lacrimal, and nasal symptoms. We transcribed audiotapes and conducted qualitative analyses to identify codes and themes. RESULTS We identified eight broad themes from the qualitative analyses. Themes reflecting physical symptoms included dry mouth, salivary gland dysfunction, altered taste, eye symptoms such as tearing or dryness, and epistaxis. Psychosocial themes included lack of knowledge and preparation for treatment, regret of treatment, and distress that thyroid cancer is labeled as a "good cancer." CONCLUSIONS Thyroid cancer survivors reported a wide range of radioactive iodine treatment-related effects and psychosocial concerns that appear to reduce quality of life. The psychosocial concerns reported by participants underscore the significant unmet information and support needs prior to and following RAI treatment among individuals diagnosed with thyroid cancer. IMPLICATIONS FOR CANCER SURVIVORS Future research is needed to help both patients and physicians understand the effect of radioactive iodine on quality of life, and to better assess the benefits versus the risks of radioactive iodine therapy.
Collapse
|
14
|
Yu CY, Saeed O, Goldberg AS, Farooq S, Fazelzad R, Goldstein DP, Tsang RW, Brierley JD, Ezzat S, Thabane L, Goldsmith CH, Sawka AM. A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. Thyroid 2018; 28:1662-1673. [PMID: 30370820 DOI: 10.1089/thy.2018.0244] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Background: The potential risk of subsequent malignant neoplasms (SMNs) after radioactive iodine (RAI) treatment of thyroid cancer (TC) is an important concern. Methods: A systematic review was updated comparing the risk of SMNs in TC patients treated with RAI to TC patients without RAI. Six electronic databases were searched (up to March, 2018), supplemented with a hand search. Two reviewers independently screened citations, reviewed full-text papers, and critically appraised/abstracted data. Random-effects meta-analyses were conducted using crude data and data statistically adjusted for confounders. The outcomes were any SMN and specific SMNs for which sufficient data were available. Results: In total, 3506 unique electronic search citations and 93 full-text papers were examined, including 17 studies (3 systematic reviews and 14 original studies). Published knowledge syntheses were limited by inclusion of small numbers of studies, with two systematic reviews suggesting an increased risk of any SMN and one meta-analysis suggesting a reduced risk of breast SMN after RAI treatment. In a meta-analysis of crude data, the risk ratio of any SMN in RAI-treated TC patients was 0.98 ([confidence interval (CI) 0.76-1.27]; n = 10 studies of 65,539 individuals, heterogeneity Q = 64.26, degrees of freedom [df] = 9, p < 0.001, I2 = 85.99). The pooled risk ratio for any SMN, adjusted for confounders, was 1.16 ([CI 0.97-1.39]; n = 6 studies, data from at least 11,241 TC patients, Q = 10.86, df = 5, p = 0.054, I2 = 53.96). In secondary analyses examining specific SMNs, although relatively rare, the risk of subsequent leukemia was increased, but the risk of multiple myeloma was reduced in RAI-treated TC patients. There was no significant increased relative risk of breast cancer, salivary cancer, or combined hematologic malignancies according to RAI treatment status. Conclusions: The body of evidence on whether 131I treatment of thyroid cancer is associated with the primary outcome of any SMN is highly heterogeneous and complex. More research examining the long-term risk of specific SMNs after 131I treatment is needed.
Collapse
Affiliation(s)
- Chi Yun Yu
- Medical School, University of Toronto, Toronto, Canada
| | - Omar Saeed
- Endocrinology Fellowship, University of Toronto, Toronto, Canada
| | | | - Shafaq Farooq
- Department of Endocrinology, University Health Network, Toronto, Canada
| | - Rouhi Fazelzad
- Library and Information Services, Princess Margaret Cancer Centre, Toronto, Canada
| | - David P Goldstein
- Department of Otolaryngology-Head and Neck Surgery, University Health Network, Toronto, Canada
| | - Richard W Tsang
- Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Canada
| | - James D Brierley
- Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Canada
| | - Shereen Ezzat
- Department of Endocrine Oncology, Princess Margaret Cancer Centre, Toronto, Canada
| | - Lehana Thabane
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada
| | - Charlie H Goldsmith
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada
- GoldStats Consulting, Simon Fraser University, and University of British Columbia, Vancouver, Canada
| | - Anna M Sawka
- Department of Endocrinology, University Health Network, Toronto, Canada
| |
Collapse
|
15
|
Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D’Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res 2018; 74:130-136. [PMID: 30055822 PMCID: PMC6219911 DOI: 10.1016/j.leukres.2018.07.016] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Revised: 06/26/2018] [Accepted: 07/17/2018] [Indexed: 01/01/2023]
Abstract
BACKGROUND Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). METHODS 9028 recipients of hematopoietic cell autotransplants (1995-2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. RESULTS 335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR = 4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR = 2.5 [1.1, 2.5]); (2) ≥3 versus 1 line of chemotherapy for NHL (HR = 1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005-2010 versus 1995-1999 (HR = 2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/MDS in HL, NHL and PCM to be 5-10 times the background rate. In contrast, relative risks were 10-50 for AML and approximately 100 for MDS in the autotransplant cohort. CONCLUSIONS There are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM.
Collapse
Affiliation(s)
- Tomas Radivoyevitch
- Dept. of Translational Hematology & Oncology Research, Cleveland Clinic Foundation, Cleveland, OH
| | - Robert M. Dean
- Dept. of Translational Hematology & Oncology Research, Cleveland Clinic Foundation, Cleveland, OH
| | - Bronwen E. Shaw
- CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
| | - Ruta Brazauskas
- CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
- Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI
| | - Heather R. Tecca
- CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
| | - Remco J. Molenaar
- Dept. of Translational Hematology & Oncology Research, Cleveland Clinic Foundation, Cleveland, OH
- Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands
| | - Minoo Battiwalla
- Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD
| | - Bipin N. Savani
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Mary E. D. Flowers
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Kenneth R. Cooke
- Pediatric Blood and Marrow Transplantation Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - Betty K. Hamilton
- Blood & Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio
| | - Matt Kalaycio
- Blood & Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio
| | | | - Ibrahim Ahmed
- Department of Hematology Oncology and Bone Marrow Transplantation, The Children’s Mercy Hospitals and Clinics, Kansas City, MO
| | - Görgün Akpek
- Stem Cell Transplantation and Cell Therapy, Rush University Medical Center, Chicago, IL
| | - Ashish Bajel
- Royal Melbourne Hospital City Campus, Melbourne, Australia
| | - David Buchbinder
- Division of Pediatrics Hematology, Children’s Hospital of Orange County, Orange, CA
| | - Jean-Yves Cahn
- Department of Hematology, CHU Grenoble Alpes, Grenoble, France
| | - Anita D’Souza
- CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
| | - Andrew Daly
- Tom Baker Cancer Center, Calgary, AB, Canada
| | - Zachariah DeFilipp
- Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA
| | - Siddhartha Ganguly
- Blood and Marrow Transplantation, University of Kansas Medical Center, Kansas City, KS
| | - Mehdi Hamadani
- CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
| | - Robert J. Hayashi
- Department of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Peiman Hematti
- Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI
| | - Yoshihiro Inamoto
- Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
| | - Nandita Khera
- Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ
| | - Tamila Kindwall-Keller
- Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA
| | - Heather Landau
- Bone Marrow Transplant Service, Division of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Hillard Lazarus
- Seidman Cancer Center, Case Western Reserve University, Cleveland, OH
| | | | - David I. Marks
- Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom
| | - Richard F. Olsson
- Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
- Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden
| | - Sachiko Seo
- Department of Hematology & Oncology; National Cancer Research Center East, Chiba, Japan
| | - Amir Steinberg
- Department of Hematology-Oncology, Mount Sinai Hospital, New York, NY
| | | | - Baldeep Wirk
- Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA
| | - Jean A. Yared
- Department of Medicine, University of Maryland, Baltimore, MD
| | - Mahmoud Aljurf
- Department of Oncology, King Faisal Specialist Hospital,, Riyadh, Saudi Arabia
| | - Muneer H. Abidi
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | | | | | - Rachel Cook
- Oregon Health and Science University, Portland, OR
| | - Robert F. Cornell
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | | | - Gregory Hale
- Department of Hematology/Oncology, Johns Hopkins All Children’s Hospital, St. Petersburg, FL
| | | | - Sonata Jodele
- Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
| | | | - Anuj Mahindra
- Scripps Blood & Marrow Transplant Program, La Jolla, CA
| | - Adriana K. Malone
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
| | | | - J. Douglas Rizzo
- CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
| | - Harry C. Schouten
- Department of Hematology, Academische Ziekenhuis, Maastricht, Netherlands
| | - Anne B. Warwick
- Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD
| | - William A. Wood
- University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - Mikkael A. Sekeres
- Dept. of Translational Hematology & Oncology Research, Cleveland Clinic Foundation, Cleveland, OH
| | | | - Robert P. Gale
- Department of Medicine, Imperial College London, London, United Kingdom
| | - Shahrukh K. Hashmi
- Department of Oncology, King Faisal Specialist Hospital,, Riyadh, Saudi Arabia
| |
Collapse
|
16
|
Verburg FA, Giovanella L, Iakovou I, Konijnenberg MW, Langsteger W, Lassmann M, Mihailovic J, Luster M. I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an “inconvenient” truth? Eur J Nucl Med Mol Imaging 2018; 45:2247-2249. [DOI: 10.1007/s00259-018-4184-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Accepted: 09/27/2018] [Indexed: 11/29/2022]
|
17
|
Tulchinsky M, Baum RP, Bennet K, Freeman LM, Jong I, Kairemo K, Marcus CS, Moadel RM, Suman P. Well-Founded Recommendations for Radioactive Iodine Treatment of Differentiated Thyroid Cancer Require Balanced Study of Benefits and Harms. J Clin Oncol 2018; 36:1887-1888. [DOI: 10.1200/jco.2018.78.5972] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Mark Tulchinsky
- Mark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los
| | - Richard P. Baum
- Mark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los
| | - K.G. Bennet
- Mark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los
| | - Leonard M. Freeman
- Mark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los
| | - Ian Jong
- Mark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los
| | - Kalevi Kairemo
- Mark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los
| | - Carol S. Marcus
- Mark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los
| | - Renee M. Moadel
- Mark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los
| | - Paritosh Suman
- Mark Tulchinsky, Pennsylvania State University, Hershey, PA; Richard P. Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, Germany; K.G. Bennet, American College of Nuclear Medicine, Downers Grove, IL; Leonard M. Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health, Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; Carol S. Marcus, David Geffen School of Medicine at University of California, Los
| |
Collapse
|
18
|
Sollini M, Chiti A. Concerns About the Risk of Myeloid Malignancies After Radioiodine Therapy in Thyroid Cancer. J Clin Oncol 2018; 36:1885-1886. [PMID: 29723098 DOI: 10.1200/jco.2018.78.1419] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Martina Sollini
- Martina Sollini, Humanitas University, Milan, Italy; and Arturo Chiti, Humanitas University and Humanitas Clinical and Research Hospital, Milan, Italy
| | - Arturo Chiti
- Martina Sollini, Humanitas University, Milan, Italy; and Arturo Chiti, Humanitas University and Humanitas Clinical and Research Hospital, Milan, Italy
| |
Collapse
|
19
|
Piccardo A, Puntoni M, Verburg FA, Luster M, Giovanella L. Power of Absolute Values to Avoid Data Misinterpretations: The Case of Radioiodine-Induced Leukemia and Myelodysplasia. J Clin Oncol 2018; 36:1880-1881. [PMID: 29723094 DOI: 10.1200/jco.2018.77.7318] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Arnoldo Piccardo
- Arnoldo Piccardo and Matteo Puntoni, Ente Ospedaliero Ospedali Galliera, Genoa, Italy; Frederik A. Verburg and Markus Luster, University Hospital Marburg, Marburg, Germany, and European Association of Nuclear Medicine, Vienna, Austria; and Luca Giovanella, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, and European Association of Nuclear Medicine, Vienna, Austria
| | - Matteo Puntoni
- Arnoldo Piccardo and Matteo Puntoni, Ente Ospedaliero Ospedali Galliera, Genoa, Italy; Frederik A. Verburg and Markus Luster, University Hospital Marburg, Marburg, Germany, and European Association of Nuclear Medicine, Vienna, Austria; and Luca Giovanella, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, and European Association of Nuclear Medicine, Vienna, Austria
| | - Frederik A Verburg
- Arnoldo Piccardo and Matteo Puntoni, Ente Ospedaliero Ospedali Galliera, Genoa, Italy; Frederik A. Verburg and Markus Luster, University Hospital Marburg, Marburg, Germany, and European Association of Nuclear Medicine, Vienna, Austria; and Luca Giovanella, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, and European Association of Nuclear Medicine, Vienna, Austria
| | - Markus Luster
- Arnoldo Piccardo and Matteo Puntoni, Ente Ospedaliero Ospedali Galliera, Genoa, Italy; Frederik A. Verburg and Markus Luster, University Hospital Marburg, Marburg, Germany, and European Association of Nuclear Medicine, Vienna, Austria; and Luca Giovanella, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, and European Association of Nuclear Medicine, Vienna, Austria
| | - Luca Giovanella
- Arnoldo Piccardo and Matteo Puntoni, Ente Ospedaliero Ospedali Galliera, Genoa, Italy; Frederik A. Verburg and Markus Luster, University Hospital Marburg, Marburg, Germany, and European Association of Nuclear Medicine, Vienna, Austria; and Luca Giovanella, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, and European Association of Nuclear Medicine, Vienna, Austria
| |
Collapse
|
20
|
Hindié E, Récher C, Zerdoud S, Leenhardt L, Avram AM. Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning. J Clin Oncol 2018; 36:1881-1882. [PMID: 29723097 DOI: 10.1200/jco.2018.78.1096] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Elif Hindié
- Elif Hindié, Bordeaux University Hospitals, Hôpital Haut-Lévêque, Pessac, France; Christian Récher and Slimane Zerdoud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Laurence Leenhardt, Pitié Salpêtrière University Hospital, Paris, France; and Anca M. Avram, University of Michigan, Ann Arbor, MI
| | - Christian Récher
- Elif Hindié, Bordeaux University Hospitals, Hôpital Haut-Lévêque, Pessac, France; Christian Récher and Slimane Zerdoud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Laurence Leenhardt, Pitié Salpêtrière University Hospital, Paris, France; and Anca M. Avram, University of Michigan, Ann Arbor, MI
| | - Slimane Zerdoud
- Elif Hindié, Bordeaux University Hospitals, Hôpital Haut-Lévêque, Pessac, France; Christian Récher and Slimane Zerdoud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Laurence Leenhardt, Pitié Salpêtrière University Hospital, Paris, France; and Anca M. Avram, University of Michigan, Ann Arbor, MI
| | - Laurence Leenhardt
- Elif Hindié, Bordeaux University Hospitals, Hôpital Haut-Lévêque, Pessac, France; Christian Récher and Slimane Zerdoud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Laurence Leenhardt, Pitié Salpêtrière University Hospital, Paris, France; and Anca M. Avram, University of Michigan, Ann Arbor, MI
| | - Anca M Avram
- Elif Hindié, Bordeaux University Hospitals, Hôpital Haut-Lévêque, Pessac, France; Christian Récher and Slimane Zerdoud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Laurence Leenhardt, Pitié Salpêtrière University Hospital, Paris, France; and Anca M. Avram, University of Michigan, Ann Arbor, MI
| |
Collapse
|
21
|
Molenaar RJ, Sidana S, Radivoyevitch T, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S. Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al. J Clin Oncol 2018; 36:1889-1892. [PMID: 29723096 DOI: 10.1200/jco.2018.78.4074] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Remco J Molenaar
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Surbhi Sidana
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Tomas Radivoyevitch
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Aaron T Gerds
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Hetty E Carraway
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Matt Kalaycio
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Aziz Nazha
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - David J Adelstein
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Christian Nasr
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Jaroslaw P Maciejewski
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Navneed S Majhail
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Mikkael A Sekeres
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| | - Sudipto Mukherjee
- Remco J. Molenaar, Cleveland Clinic, Cleveland, Ohio, and University of Amsterdam, Amsterdam, the Netherlands; Surbhi Sidana, Cleveland Clinic, Cleveland, Ohio, and Mayo Clinic, Rochester, MN; and Tomas Radivoyevitch, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Aziz Nazha, David J. Adelstein, Christian Nasr, Jaroslaw P. Maciejewski, Navneed S. Majhail, Mikkael A. Sekeres, and Sudipto Mukherjee, Cleveland Clinic, Cleveland, Ohio
| |
Collapse
|
22
|
Teepen JC, Curtis RE, Dores GM, Berrington de Gonzalez A, van den Heuvel-Eibrink MM, Kremer LCM, Gilbert ES, van Leeuwen FE, Ronckers CM, Morton LM. Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014. Leukemia 2018; 32:2580-2589. [PMID: 29795414 DOI: 10.1038/s41375-018-0149-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2017] [Revised: 03/24/2018] [Accepted: 04/11/2018] [Indexed: 12/31/2022]
Abstract
Although increased risk of acute myeloid leukemia (AML) has been observed after chemotherapy and radiotherapy, less is known about radiotherapy-related risks of specific AML subtypes and other specific myeloid neoplasms. We used the US population-based cancer registry data to evaluate risk of myeloid neoplasms among three cohorts of cancer survivors initially treated with radiotherapy only. We included 1-year survivors of first primary thyroid (radioiodine only, stages I-IV; N = 49 879), prostate (excluding stage IV; N = 237 439), or uterine corpus cancers (stage I-II; N = 16 208) diagnosed during 2000-2013. We calculated standardized incidence ratios (SIRs) and excess absolute risks (EARs). Thyroid cancer survivors had significantly elevated risks of total AML (SIR = 2.77, 95% CI: 1.99-3.76), AML with cytogenetic abnormalities (SIR = 3.90, 95% CI: 1.57-8.04), AML with myelodysplasia-related changes (SIR = 2.87, 95% CI: 1.05-6.25), and BCR-ABL1-positive chronic myelogenous leukemia (CML) (SIR = 5.38, 95% CI: 2.58-9.89). Irradiated prostate and uterine corpus cancer survivors were at elevated risk for total AML (SIR = 1.14, 95% CI: 1.03-1.27 and SIR = 1.77, 95% CI: 1.01-2.87, respectively), AML with cytogenetic abnormalities (SIR = 2.52, 95% CI: 1.84-3.37 and SIR = 7.21, 95% CI: 2.34-16.83, respectively), and acute promyelocytic leukemia (SIR = 3.20, 95% CI: 2.20-4.49 and SIR = 8.88, 95% CI: 2.42-22.73, respectively). In addition, prostate cancer survivors were at increased risk of BCR-ABL1-positive CML (SIR = 2.11, 95% CI: 1.52-2.85). Our findings support the importance of diagnostic precision in myeloid neoplasm classification since susceptibility following radiotherapy may vary by myeloid neoplasm subtype, thereby informing risk/benefit discussions in first primary cancer treatment.
Collapse
Affiliation(s)
- Jop C Teepen
- Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands. .,Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
| | - Rochelle E Curtis
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
| | - Graça M Dores
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
| | - Amy Berrington de Gonzalez
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
| | | | - Leontien C M Kremer
- Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands.,Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - Ethel S Gilbert
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
| | - Flora E van Leeuwen
- Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Cécile M Ronckers
- Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands
| | - Lindsay M Morton
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
| |
Collapse
|
23
|
Tulchinsky M, Binse I, Campennì A, Dizdarevic S, Giovanella L, Jong I, Kairemo K, Kim CK. Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy. J Nucl Med 2018; 59:723-725. [PMID: 29653977 DOI: 10.2967/jnumed.118.211359] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2018] [Accepted: 03/26/2018] [Indexed: 11/16/2022] Open
Affiliation(s)
- Mark Tulchinsky
- Section of Nuclear Medicine, Department of Radiology, Pennsylvania State University, Hershey, Pennsylvania
| | - Ina Binse
- Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
| | - Alfredo Campennì
- Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
| | - Sabina Dizdarevic
- Imaging and Nuclear Medicine Department, Brighton and Sussex University Hospitals, Brighton and Sussex Medical School, Brighton, United Kingdom
| | - Luca Giovanella
- EOC Thyroid Diagnosis and Therapy Centre, Nuclear Medicine and PET/CT Centre, Oncology Institute of Southern Switzerland, Bellinzona and Lugano, Switzerland
| | - Ian Jong
- Nuclear Medicine Department, Monash Health, Melbourne, Victoria, Australia
| | - Kalevi Kairemo
- Docrates Cancer Center, Molecular Radiotherapy and Nuclear Medicine, Helsinki, Finland; and
| | - Chun K Kim
- Department of Nuclear Medicine, Hanyang University College of Medicine, Seoul, Korea
| |
Collapse
|